Eli LillyLLY
NYSE · USA · Segment 1 of 8 in the Medicine, pharma & life science value chain: Diabetes & metabolic disease
Mounjaro and Zepbound put Lilly at the centre of the GLP-1 market. Around them sit the diabetes and insulin business and franchises in oncology and neurology, with a pipeline that ranks among the strongest in the industry.
Diabetes & metabolic disease: Treatment and monitoring of diabetes and metabolic disease, from insulin to glucose monitoring.
Key metrics
Market cap
$1.2T
Price
$1,246.93
Today
−0.7%
Return YTD
+16.8%
Return 1Y
+76.9%
P/E
43.2
P/S
14.5
P/B
34.0
Data as of 2026-08-25 · updates daily after U.S. close
Theme exposure
In the value chain
Supply chain
Supplies →
← Suppliers
Same segment: Diabetes & metabolic disease
Compare LLY
See where Eli Lilly sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →